SEARCH

SEARCH BY CITATION

References

  • 1
    Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Developed for the Global Initiative for Asthma (GINA). Available at: http://www.ginasthma.com (Accessed 1 December 2006).
  • 2
    Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636642.
  • 3
    Lodha R, Puranik M, Kattal N, Kabra SK. Social and economic impact of childhood asthma. Indian Pediatr 2003;40:874879.
  • 4
    Larbanois A, Jamart J, Delwiche JP, Vandenplas O. Socioeconomic outcome of subjects experiencing asthma symptoms at work. Eur Respir J 2002;19:11071113.
  • 5
    Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J 2003;21:10001006.
  • 6
    Wang LY, Zhong Y, Wheeler L. Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2005;2:A11.
  • 7
    Herjavecz I, Nagy GB, Gyurkovits K, Magyar P, Dobos K, Nagy L et al. Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma 2003;40:673681.
  • 8
    Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001;79:971979.
  • 9
    Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005;83:548554.
  • 10
    Ait-Khaled N, Enarson DA, Bencharif N, Boulahdib F, Camara LM, Dagli E et al. Implementation of asthma guidelines in health centres of several developing countries. Int J Tuberc Lung Dis 2006;10:104109.
  • 11
    Ait-Khaled N, Enarson DA, Bencharif N, Boulahdib F, Camara LM, Dagli E et al. Treatment outcome of asthma after one year follow-up in health centres of several developing countries. Int J Tuberc Lung Dis 2006;10:911916.
  • 12
    Sterk PJ, Buist SA, Woolcock AJ, Marks GB, Platts-Mills TAE, Von Mutius E et al. The message from the World Asthma Meeting. The Working Groups of the World Asthma Meeting, held in Barcelona, Spain, December 9–13, 1998. Eur Respir J 1999;14:14351453.
  • 13
    The International Study of Asthma and Allergies in Children (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: (ISAAC). Lancet 1998;351:12251232.
  • 14
    Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161176.
  • 15
    The International Study of Asthma and Allergies in Childhood Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998;12:315335.
  • 16
    Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733743.
  • 17
    Ottmani SE, Scherpbier R, Pio A, Chaulet P, Ait-Khaled N, Blanc L et al. Practical Approach to Lung Health (PAL): a primary health care strategy for the integrated management of respiratory conditions in people five years of age and over. WHO/HTM/TB/2005.351. Geneva: World Health Organization, 2005.
  • 18
    Ottmani SE, Scherpbier R, Chaulet P, Pio A, Van Beneden C, Raviglione M. Practical Approach to Lung Health. Respiratory care in primary care services – a survey in 9 countries. WHO/HTM/TB/2004.333. Geneva: World Health Organization, 2004.
  • 19
    Sears MR. Worldwide trend in asthma mortality. Bull Int Union Tuberc Lung Dis 1991;66:7989.
  • 20
    Sly RM. Increases in deaths from asthma. Ann Allergy 1984;53:2025.
  • 21
    Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983–95: results of an observational study. BMJ 1997;314:14391441.
  • 22
    Anderson HR. Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmissions from 1970 to 1985 in a health region of the United Kingdom. Thorax 1989;44:614661.
  • 23
    Gilthorpe MS, Lay-Yee R, Wilson RC, Walters S, Griffiths RK, Bedi R. Variations in hospitalization rates for asthma among black and minority ethic communities. Respir Med 1998;92:642648.
  • 24
    Partridge MR. In what way may race, ethnicity or culture influence asthma outcomes? Thorax 2000;55:175176.
  • 25
    Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862866.
  • 26
    Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. Eur Respir J 2005;25:4753.
  • 27
    Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics 1993;4:1430.
  • 28
    Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Cost of asthma according to the degree of severity. Eur Respir J 1998;12:13221326.
  • 29
    Chouaid C, Vergnenegre A, Vanderwalle V, Liebaert F, Khelifa A, Galipon et al. The costs of asthma in France: an economic analysis by a Markov model. Rev Mal Respir 2004;21(3 Pt 1):493499.
  • 30
    Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F et al. Asthma severity and medical resource utilization. Eur Respir J 2004;23:723729.
  • 31
    Schwenkglenks M, Lowy A, Anderhub H, Szucs TD. Cost of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health 2003;6:7583.
  • 32
    Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994;72:429445.
  • 33
    World Health Organization. The world health report 2000: health systems: improving performance. Geneva: World Health Organization, 2000 (ISBN 92 4 156198 X).
  • 34
    Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health. National Heart Lung and Blood Institute. Updated from NHLBI/WHO Workshop Report, Issued January 1995. Revised Report 2002. Available at: http://www.ginasthma.com
  • 35
    Adelroth E, Thomson S. Advantages of high-dose inhaled budesonide. Lancet 1988;2:476 (Letter).
  • 36
    Ait-Khaled N, Enarson DA. Management of asthma in adults: a guide for low income countries. International Union Against Tuberculosis and Lung Disease. Frankfurt am Main: pmi-Verl.-Gruppe, 1996.
  • 37
    Ait-Khaled N, Enarson DA. Management of asthma: a guide to the essentials of good clinical practice. Paris, France: International Union Against Tuberculosis and Lung Disease, 2005. Available at: http://www.iuatld.org
  • 38
    Ait-Khaled N, Auregan G, Bencharif N, Camara LM, Dagli E, Djankine K et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000;4:268271.
  • 39
    Burney P. Global Asthma Survey on Practice. 35th Union World Conference on Lung Health; 28 Oct–1 Nov 2004, Paris, France (personal communication).
  • 40
    Schatz M, Cook EF, Joshua A, Petitti D. Risk factors for asthma hospitalizations in a managed care organization: development of a clinical prediction rule. Am J Manag Care 2003;9:538547.
  • 41
    Ather S, Chung KD, Gregory P, Demissie K. The association between hospital readmission and insurance provider among adults with asthma. J Asthma 2004;41:709713.
  • 42
    Billo N. Do we need an Asthma Drug Facility? Int J Tuberc Lung Dis 2004;8:391.
  • 43
    Billo NE. Asthma Drug Facility: from concept to reality. Int J Tuberc Lung Dis 2006;10:709.
  • 44
    Trébucq A, Rambert C. A guide for the procurement of anti-tuberculosis drugs. Paris, France: International Union Against Tuberculosis and Lung Disease, 2001. Available at: http://www.iuatld.org
  • 45
    Kumaresan J, Smith I, Arnold V, Evans P. The global TB drug facility: innovative global procurement. Int J Tuberc Lung Dis 2004;8:130138.
  • 46
    Lavallée M. Transition vers des aérosols-doseurs sans CFC: comment s'y retrouver? Pharmactuel 2003;36:113114.
  • 47
    Dolovich M. New delivery systems and propellants. Can Respir J 1999;6:290295.
  • 48
    Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996;41:247249.
  • 49
    Baumgarten CR, Dorow P, Weber HH, Gebhardt R, Kettner J, Sykes AP, German Study Group. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Respir Med 2000;94 (Suppl B):S1721.
  • 50
    Donnell D, Harrison LI, Ward S, Klinger NM, Ekholm BP, Cooper KM et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur J Clin Pharmacol 1995;48:473477.
  • 51
    Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109:702707.
  • 52
    Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:13461353.
  • 53
    Derom E, Pauwels RA. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin Pharmacokinet 2005;44:815836.
  • 54
    Holz O, Zuhlke I, Einhaus M, Welker L, Kanniess F, Branscheid D et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004;17:233238.
  • 55
    Boulet LP, Cartier A, Ernst P, Larivee P, Laviolette M. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months. Can Respir J 2004;11:123130.
  • 56
    Demedts M, Cohen R, Hawkinson R Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract 1999;53:331338.
  • 57
    Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001;86:557565.
  • 58
    Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol 1999;51:263269.
  • 59
    Ederle K, Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. Eur Rev Med Pharmacol Sci 2003;7:4555.
  • 60
    Malone DC, Luskin AT. Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. Respir Med 2003;97:12691276.
  • 61
    Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002;20:653664 (Erratum in: Pharmacoeconomics 2002;20:853).
  • 62
    World Health Organization. Preventing chronic diseases: a vital investment: WHO Global Report. Geneva: World Health Organization, 2005 (ISBN 92 4 156300 1).
  • 63
    Global Alliance against Chronic Respiratory Diseases (GARD). Available at: http://www.who.int/respiratory/gard/launch/en/index.html (Accessed 1 December 2006).